Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06099652
Other study ID # SSGJ-611-COPD-II-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 8, 2023
Est. completion date May 2025

Study information

Verified date October 2023
Source Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Contact Qinghong Zhou, BS
Phone +86 18911301578
Email zhouqinghong@3sbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.


Description:

The maximum study duration was 28 weeks per participants, including a screening period of up to 4 weeks, a 16-week randomized treatment period, and a 8-week follow-up period.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date May 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria: 1. Subject must be able to understand and comply with the requirements of the study. and must participate voluntarily and sign the written informed consent. 2. Male or female adults ages 40 to 85 years old when signing the informed consent. 3. BMI=16 kg/m2. 4. Documented diagnosis of COPD for at least one year prior to enrolment. 5. Post-bronchodilator FEV1/FVC < 0.70 and post-bronchodilator FEV1 % predicted >30% and =70%. 6. Current or former smokers with a smoking history of =10 pack-years or environmental exposure to biofuel fumes =10 years 7. Documented history of = 2 moderate or = 1 severe COPD exacerbations within 12 months prior to enrolment. 8. Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for =1 month prior to randomization; Double therapy (LABA + LAMA) allowed if ICS is contraindicated. 9. Patients with blood eosinophils =200 cells/microliter at screening. 10. Female subjects of reproductive age (and their male partners) and male subjects (and their female partners) must use highly effective contraception throughout the study period and for at least 3 months after the last dose. The subjects had no plans to pregnancy, donate sperm or donate egg during the whole study period and for at least 3 months after the last dose. Exclusion Criteria: 1. Significant pulmonary disease other than COPD (e.g., active tuberculosis,lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease, etc) 2. Diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts. 3. A current diagnosis of asthma or history of asthma according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines. 4. Diagnosis of a-1 anti-trypsin deficiency. 5. Cor pulmonale, evidence of right cardiac failure 6. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). 7. A participant with a history of clinically significant renal, hepatic, cardiovascular, metabolic, neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular or other significant medical illness or disorder which, in the judgment of the Investigator, could interfere with the study or require treatment that might interfere with the study. 8. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening. 9. Hypercapnia requiring Bi-level ventilation. 10. AECOPD as defined in inclusion criteria within 4 weeks prior to screening or randomization. 11. History of, or planned pneumonectomy or lung volume reduction surgery. 12. Treatment with oxygen of more than 12 hours per day. 13. Known with allergic or intolerant to mometasone furoate spray or 611/placebo. 14. Any reason which, in the opinion of investigator, would prevent the subject from participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
611 300 mg Q2W
611 subcutaneous (SC) injection
611 450 mg Q2W
611 subcutaneous (SC) injection
Matching placebo
placebo subcutaneous (SC) injection

Locations

Country Name City State
China China-Japan Friendship Hospital Beijing Beijing
China Zhongshan Hospital affiliated to Fudan University Shanghai Shanghai
China Shenzhen People's Hospital Shenzhen Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in pre-bronchodilator FEV1 at Week 16 FEV1 is the Forced expiratory volume in one second at study site up to Week 16
Secondary Change from baseline in Chronic Obstructive Pulmonary Disease assessment tool (CAT) score Chronic Obstructive Pulmonary Disease assessment tool (CAT) score ranges from 0 to 40, a higher score indicating a higher impact on health status. up to Week 16
Secondary Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score St. George's Respiratory Questionnaire (SGRQ) is a questionnaire designed to measure and quantify health-related health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100. Lower score indicates better quality of life. up to Week 16
Secondary Percentage of participants with a decrease in SGRQ total score of = 4 points from baseline to Week 16 St. George's Respiratory Questionnaire (SGRQ) is a questionnaire designed to measure and quantify health-related health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100. Lower score indicates better quality of life. up to Week 16
Secondary Annualized rate of moderate to severe COPD exacerbations in participants Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD.
Moderate:Use of systemic corticosteroids; and/or use of antibiotics; Severe:An inpatient hospitalization due to COPD
up to Week 16
Secondary Time to first Moderate or severe COPD exacerbation Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD.
Moderate:Use of systemic corticosteroids; and/or use of antibiotics; Severe:An inpatient hospitalization due to COPD
up to Week 16
Secondary Adverse events (AEs), measurement of vital signs,physical examination,electrocardiogram and laboratory tests at each visit. The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations,electrocardiogram,laboratory tests and, etc. Up to 24 Weeks
Secondary 611 Concentration in Serum The concentration of 611 in Serum Up to 24 Weeks
Secondary Percentage of Participants with Anti-drug Antibodies and Neutralizing Antibodies Immunogenicity assessment will be based on Anti-drug Antibodies (ADAs) response and development of Neutralizing Antibodies (NABs). Percentage is calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-drug antibodies / number of evaluable participants * 100%. Up to 24 Weeks
Secondary Change in serum concentrations of PD variables PD variables included Pulmonary and activation-regulated chemokine (PARC),IgE,blood eosinophil counts and fibrinogen Up to 24 Weeks
See also
  Status Clinical Trial Phase
Completed NCT05043428 - The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD N/A
Completed NCT00528996 - An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. Phase 2
Completed NCT03740373 - A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate Phase 1
Completed NCT05402020 - Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
Completed NCT05393245 - Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
Completed NCT04011735 - Re-usable Respimat® Soft MistTM Inhaler Study
Enrolling by invitation NCT03075709 - The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
Completed NCT03764163 - Image and Model Based Analysis of Lung Disease Early Phase 1
Completed NCT00515268 - Endotoxin Challenge Study For Healthy Men and Women Phase 1
Completed NCT04085302 - TARA Working Prototype Engagement Evaluation: Feasibility Study N/A
Completed NCT03691324 - Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study N/A
Completed NCT02236611 - A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT00153075 - Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT01009463 - A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT01017952 - A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT04882124 - Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD Phase 2
Completed NCT02853123 - Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients Phase 4
Completed NCT02619357 - Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma Phase 1
Recruiting NCT05858463 - High Intensity Interval Training and Muscle Adaptations During PR N/A
Not yet recruiting NCT05032898 - Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II